{
    "nct_id": "NCT06881784",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2025-03-18",
    "study_start_date": "2025-05-06",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: docetaxel"
            },
            {
                "drug_name": "Drug: daraxonrasib"
            }
        ]
    },
    "long_title": "RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",
    "last_updated": "2025-10-22",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Revolution Medicines, Inc.",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 420,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* At least 18 years old and has provided informed consent.",
        "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
        "* Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.",
        "* Measurable disease per RECIST v1.1.",
        "* Adequate organ function (bone marrow, liver, kidney, coagulation).",
        "* One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy.",
        "* Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61).",
        "* Able to take oral medications.",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Prior therapy with direct RAS-targeted therapy or docetaxel.",
        "Exclude - * Untreated central nervous system (CNS) metastases.",
        "Exclude - * Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function).",
        "Exclude - * Ongoing anticancer therapy.",
        "Exclude - * Pregnant or breastfeeding."
    ],
    "short_title": "Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Revolution Medicines, Inc.",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "daraxonrasib",
                        "arm_internal_id": 0,
                        "arm_description": "study drug",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: daraxonrasib",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "docetaxel",
                        "arm_internal_id": 1,
                        "arm_description": "Patients randomized to the comparator control arm will receive docetaxel as the standard of care therapy.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: docetaxel",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Locally Advanced",
                                        "Metastatic",
                                        "Untreated"
                                    ],
                                    "oncotree_primary_diagnosis": "Non-Small Cell Lung Cancer"
                                }
                            },
                            {
                                "or": [
                                    {
                                        "genomic": {
                                            "hugo_symbol": "KRAS",
                                            "variant_category": "Mutation"
                                        }
                                    },
                                    {
                                        "genomic": {
                                            "hugo_symbol": "NRAS",
                                            "variant_category": "Mutation"
                                        }
                                    },
                                    {
                                        "genomic": {
                                            "hugo_symbol": "HRAS",
                                            "variant_category": "Mutation"
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        ]
    }
}